| Item Type | Name |
|
Academic Article
|
1,25-dihydroxyvitamin D3 modulates phosphorylation of serine 205 in the human vitamin D receptor: site-directed mutagenesis of this residue promotes alternative phosphorylation.
|
|
Academic Article
|
1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1.
|
|
Academic Article
|
Vitamin D and prostate cancer.
|
|
Academic Article
|
Vector-averaged gravity-induced changes in cell signaling and vitamin D receptor activity in MG-63 cells are reversed by a 1,25-(OH)2D3 analog, EB1089.
|
|
Academic Article
|
1alpha,25-dihydroxyvitamin D3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway.
|
|
Academic Article
|
Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2.
|
|
Academic Article
|
A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice.
|
|
Academic Article
|
Repressors of androgen and progesterone receptor action.
|
|
Academic Article
|
p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells.
|
|
Academic Article
|
PTHrP contributes to the anti-proliferative and integrin alpha6beta4-regulating effects of 1,25-dihydroxyvitamin D(3).
|
|
Academic Article
|
Differential skeletal responses of hindlimb unloaded rats on a vitamin D-deficient diet to 1,25-dihydroxyvitamin D3 and its analog, seocalcitol (EB1089).
|
|
Academic Article
|
Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells.
|
|
Academic Article
|
Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
|
|
Academic Article
|
1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion.
|
|
Academic Article
|
The functional consequences of cross-talk between the vitamin D receptor and ERK signaling pathways are cell-specific.
|
|
Academic Article
|
Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE.
|
|
Academic Article
|
Interactions between vitamin D and androgen receptor signaling in prostate cancer cells.
|
|
Academic Article
|
1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells.
|
|
Academic Article
|
EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells.
|
|
Academic Article
|
Novel nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium.
|
|
Academic Article
|
Vitamin D and prostate cancer.
|
|
Academic Article
|
Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
|
|
Academic Article
|
Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells.
|
|
Academic Article
|
1a,25-dihydroxyvitamin D3 inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G1 arrest.
|
|
Concept
|
Receptors, Calcitriol
|
|
Concept
|
Calcitriol
|
|
Academic Article
|
The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling.
|
|
Academic Article
|
Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG.
|